nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—PTGS2—Etoposide—uterine cancer	0.105	0.348	CbGbCtD
Lenalidomide—ABCB1—Progesterone—uterine cancer	0.0775	0.256	CbGbCtD
Lenalidomide—ABCB1—Dactinomycin—uterine cancer	0.0615	0.203	CbGbCtD
Lenalidomide—ABCB1—Etoposide—uterine cancer	0.0347	0.115	CbGbCtD
Lenalidomide—ABCB1—Doxorubicin—uterine cancer	0.0237	0.0782	CbGbCtD
Lenalidomide—CDH5—artery—uterine cancer	0.0201	0.117	CbGeAlD
Lenalidomide—TNFSF11—Differentiation Pathway—INHBA—uterine cancer	0.0101	0.0948	CbGpPWpGaD
Lenalidomide—Thalidomide—FGFR2—uterine cancer	0.0098	1	CrCbGaD
Lenalidomide—CDH5—myometrium—uterine cancer	0.00971	0.0565	CbGeAlD
Lenalidomide—CDH5—Cell junction organization—PARVA—uterine cancer	0.0087	0.0814	CbGpPWpGaD
Lenalidomide—CDH5—epithelium—uterine cancer	0.00762	0.0443	CbGeAlD
Lenalidomide—CDH5—uterine cervix—uterine cancer	0.00756	0.0439	CbGeAlD
Lenalidomide—CDH5—smooth muscle tissue—uterine cancer	0.00735	0.0427	CbGeAlD
Lenalidomide—CDH5—decidua—uterine cancer	0.0072	0.0419	CbGeAlD
Lenalidomide—TNFSF11—IL6-mediated signaling events—IRF1—uterine cancer	0.00711	0.0665	CbGpPWpGaD
Lenalidomide—CDH5—endometrium—uterine cancer	0.00684	0.0397	CbGeAlD
Lenalidomide—CDH5—mammalian vulva—uterine cancer	0.00661	0.0384	CbGeAlD
Lenalidomide—CDH5—uterus—uterine cancer	0.0063	0.0366	CbGeAlD
Lenalidomide—CDH5—Cell-Cell communication—PARVA—uterine cancer	0.0062	0.058	CbGpPWpGaD
Lenalidomide—CRBN—myometrium—uterine cancer	0.00617	0.0359	CbGeAlD
Lenalidomide—CDH5—female reproductive system—uterine cancer	0.00566	0.0329	CbGeAlD
Lenalidomide—TNFSF11—IL6-mediated signaling events—SOCS3—uterine cancer	0.00521	0.0488	CbGpPWpGaD
Lenalidomide—CDH5—female gonad—uterine cancer	0.00515	0.03	CbGeAlD
Lenalidomide—CDH5—vagina—uterine cancer	0.00512	0.0298	CbGeAlD
Lenalidomide—CRBN—uterine cervix—uterine cancer	0.0048	0.0279	CbGeAlD
Lenalidomide—CRBN—decidua—uterine cancer	0.00458	0.0266	CbGeAlD
Lenalidomide—CRBN—renal system—uterine cancer	0.00449	0.0261	CbGeAlD
Lenalidomide—TNFSF11—lymph node—uterine cancer	0.0044	0.0256	CbGeAlD
Lenalidomide—CRBN—endometrium—uterine cancer	0.00434	0.0252	CbGeAlD
Lenalidomide—CRBN—mammalian vulva—uterine cancer	0.0042	0.0244	CbGeAlD
Lenalidomide—CRBN—uterus—uterine cancer	0.004	0.0233	CbGeAlD
Lenalidomide—CRBN—female reproductive system—uterine cancer	0.0036	0.0209	CbGeAlD
Lenalidomide—CDH5—Adherens junctions interactions—CDH1—uterine cancer	0.00351	0.0328	CbGpPWpGaD
Lenalidomide—PTGS2—artery—uterine cancer	0.00348	0.0202	CbGeAlD
Lenalidomide—CDH5—lymph node—uterine cancer	0.00331	0.0193	CbGeAlD
Lenalidomide—CRBN—female gonad—uterine cancer	0.00327	0.019	CbGeAlD
Lenalidomide—CRBN—vagina—uterine cancer	0.00325	0.0189	CbGeAlD
Lenalidomide—CDH5—VEGFR2 mediated vascular permeability—CTNNB1—uterine cancer	0.00274	0.0256	CbGpPWpGaD
Lenalidomide—CDH5—Adherens junctions interactions—CTNNB1—uterine cancer	0.00259	0.0242	CbGpPWpGaD
Lenalidomide—CRBN—lymph node—uterine cancer	0.0021	0.0122	CbGeAlD
Lenalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFE2L2—uterine cancer	0.00207	0.0193	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—VEGFA—uterine cancer	0.00207	0.0193	CbGpPWpGaD
Lenalidomide—CDH5—Cell-cell junction organization—CDH1—uterine cancer	0.00202	0.0189	CbGpPWpGaD
Lenalidomide—CDH5—S1P2 pathway—PIK3CA—uterine cancer	0.002	0.0187	CbGpPWpGaD
Lenalidomide—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—AKR1C3—uterine cancer	0.00192	0.018	CbGpPWpGaD
Lenalidomide—PTGS2—myometrium—uterine cancer	0.00168	0.00977	CbGeAlD
Lenalidomide—TNFSF11—IL6-mediated signaling events—PIK3CA—uterine cancer	0.00164	0.0154	CbGpPWpGaD
Lenalidomide—CDH5—VEGFR2 mediated vascular permeability—AKT1—uterine cancer	0.00154	0.0144	CbGpPWpGaD
Lenalidomide—CDH5—Cell junction organization—CDH1—uterine cancer	0.00153	0.0143	CbGpPWpGaD
Lenalidomide—CDH5—Cell-cell junction organization—CTNNB1—uterine cancer	0.00149	0.0139	CbGpPWpGaD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—CTNNB1—uterine cancer	0.00135	0.0126	CbGpPWpGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—AKT1—uterine cancer	0.00134	0.0125	CbGpPWpGaD
Lenalidomide—PTGS2—epithelium—uterine cancer	0.00132	0.00767	CbGeAlD
Lenalidomide—PTGS2—uterine cervix—uterine cancer	0.00131	0.0076	CbGeAlD
Lenalidomide—PTGS2—smooth muscle tissue—uterine cancer	0.00127	0.00739	CbGeAlD
Lenalidomide—PTGS2—renal system—uterine cancer	0.00122	0.00711	CbGeAlD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—uterine cancer	0.00119	0.0111	CbGpPWpGaD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—AKT1—uterine cancer	0.00118	0.0111	CbGpPWpGaD
Lenalidomide—PTGS2—endometrium—uterine cancer	0.00118	0.00687	CbGeAlD
Lenalidomide—ABCB1—ABC-family proteins mediated transport—ABCC9—uterine cancer	0.00113	0.0106	CbGpPWpGaD
Lenalidomide—CDH5—Cell junction organization—CTNNB1—uterine cancer	0.00113	0.0105	CbGpPWpGaD
Lenalidomide—PTGS2—Prostaglandin Synthesis and Regulation—CYP11A1—uterine cancer	0.00111	0.0104	CbGpPWpGaD
Lenalidomide—PTGS2—uterus—uterine cancer	0.00109	0.00633	CbGeAlD
Lenalidomide—CDH5—Cell-Cell communication—CDH1—uterine cancer	0.00109	0.0102	CbGpPWpGaD
Lenalidomide—ABCB1—myometrium—uterine cancer	0.00104	0.00604	CbGeAlD
Lenalidomide—PTGS2—female reproductive system—uterine cancer	0.00098	0.00569	CbGeAlD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—CTNNB1—uterine cancer	0.000937	0.00876	CbGpPWpGaD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—PIK3CA—uterine cancer	0.000926	0.00866	CbGpPWpGaD
Lenalidomide—PTGS2—female gonad—uterine cancer	0.000891	0.00518	CbGeAlD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—NFE2L2—uterine cancer	0.000888	0.00831	CbGpPWpGaD
Lenalidomide—PTGS2—vagina—uterine cancer	0.000886	0.00515	CbGeAlD
Lenalidomide—CDH5—Signaling by VEGF—CTNNB1—uterine cancer	0.000884	0.00827	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—VEGFA—uterine cancer	0.000825	0.00772	CbGpPWpGaD
Lenalidomide—ABCB1—epithelium—uterine cancer	0.000816	0.00474	CbGeAlD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—NRAS—uterine cancer	0.000815	0.00762	CbGpPWpGaD
Lenalidomide—ABCB1—uterine cervix—uterine cancer	0.000809	0.0047	CbGeAlD
Lenalidomide—CDH5—Cell-Cell communication—CTNNB1—uterine cancer	0.000802	0.0075	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—VEGFA—uterine cancer	0.000779	0.00728	CbGpPWpGaD
Lenalidomide—ABCB1—decidua—uterine cancer	0.000771	0.00448	CbGeAlD
Lenalidomide—CDH5—Signaling by VEGF—NRAS—uterine cancer	0.000769	0.00719	CbGpPWpGaD
Lenalidomide—ABCB1—renal system—uterine cancer	0.000757	0.0044	CbGeAlD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—AKT1—uterine cancer	0.000756	0.00708	CbGpPWpGaD
Lenalidomide—ABCB1—endometrium—uterine cancer	0.000732	0.00425	CbGeAlD
Lenalidomide—ABCB1—mammalian vulva—uterine cancer	0.000708	0.00411	CbGeAlD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—KRAS—uterine cancer	0.000701	0.00656	CbGpPWpGaD
Lenalidomide—PTGS2—Arachidonic acid metabolism—AKR1C3—uterine cancer	0.000695	0.0065	CbGpPWpGaD
Lenalidomide—ABCB1—uterus—uterine cancer	0.000674	0.00392	CbGeAlD
Lenalidomide—CDH5—Signaling by VEGF—KRAS—uterine cancer	0.000662	0.00619	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—PIK3CA—uterine cancer	0.000644	0.00603	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAP3K4—uterine cancer	0.000614	0.00575	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—PIK3CA—uterine cancer	0.000608	0.00569	CbGpPWpGaD
Lenalidomide—ABCB1—female reproductive system—uterine cancer	0.000606	0.00352	CbGeAlD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—HRAS—uterine cancer	0.000596	0.00558	CbGpPWpGaD
Lenalidomide—PTGS2—lymph node—uterine cancer	0.000573	0.00333	CbGeAlD
Lenalidomide—CDH5—Signaling by VEGF—HRAS—uterine cancer	0.000563	0.00526	CbGpPWpGaD
Lenalidomide—ABCB1—female gonad—uterine cancer	0.000551	0.00321	CbGeAlD
Lenalidomide—CDH5—Cell-Cell communication—PIK3CA—uterine cancer	0.000551	0.00516	CbGpPWpGaD
Lenalidomide—ABCB1—vagina—uterine cancer	0.000548	0.00319	CbGeAlD
Lenalidomide—PTGS2—Overview of nanoparticle effects—CXCL8—uterine cancer	0.000546	0.00511	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—AKT1—uterine cancer	0.000526	0.00492	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—AKR1B10—uterine cancer	0.000522	0.00488	CbGpPWpGaD
Lenalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—uterine cancer	0.000509	0.00476	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—GPX3—uterine cancer	0.000504	0.00472	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—AKT1—uterine cancer	0.000497	0.00465	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—ESR1—uterine cancer	0.000481	0.0045	CbGpPWpGaD
Lenalidomide—PTGS2—S1P1 pathway—VEGFA—uterine cancer	0.000444	0.00415	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAP3K4—uterine cancer	0.000436	0.00407	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—RNF43—uterine cancer	0.000433	0.00405	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—INHBA—uterine cancer	0.000396	0.0037	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—ESR1—uterine cancer	0.000387	0.00362	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—AKR1C1—uterine cancer	0.000356	0.00333	CbGpPWpGaD
Lenalidomide—ABCB1—lymph node—uterine cancer	0.000354	0.00206	CbGeAlD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	0.000343	0.00321	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—AKR1C3—uterine cancer	0.000274	0.00257	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PGR—uterine cancer	0.000267	0.0025	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—CDKN1B—uterine cancer	0.000263	0.00246	CbGpPWpGaD
Lenalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—uterine cancer	0.000261	0.00244	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—MTHFR—uterine cancer	0.000259	0.00242	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—YWHAE—uterine cancer	0.000255	0.00239	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—uterine cancer	0.000252	0.00236	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—SMAD3—uterine cancer	0.000252	0.00235	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—FBXW7—uterine cancer	0.000244	0.00229	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	0.000243	0.00228	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.000243	0.00228	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—EP300—uterine cancer	0.000231	0.00216	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	0.00022	0.00206	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—uterine cancer	0.000219	0.00205	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—NRAS—uterine cancer	0.000216	0.00202	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—STK11—uterine cancer	0.000214	0.002	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—uterine cancer	0.000206	0.00192	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	0.000204	0.00191	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—CCL2—uterine cancer	0.000203	0.0019	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SOCS3—uterine cancer	0.0002	0.00187	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CDKN2B—uterine cancer	0.000192	0.00179	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IGF1R—uterine cancer	0.000186	0.00174	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—KRAS—uterine cancer	0.000186	0.00174	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	0.000185	0.00173	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CDKN2A—uterine cancer	0.000183	0.00172	CbGpPWpGaD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—uterine cancer	0.000177	0.00166	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.000176	0.00164	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.000176	0.00164	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SMAD3—uterine cancer	0.000175	0.00164	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—FGFR2—uterine cancer	0.000167	0.00156	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	0.000166	0.00155	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CDKN1B—uterine cancer	0.000162	0.00152	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CCL2—uterine cancer	0.00016	0.0015	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	0.000158	0.00148	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	0.000156	0.00146	CbGpPWpGaD
Lenalidomide—Influenza—Doxorubicin—uterine cancer	0.000154	0.000377	CcSEcCtD
Lenalidomide—Pollakiuria—Epirubicin—uterine cancer	0.000154	0.000376	CcSEcCtD
Lenalidomide—Photosensitivity reaction—Epirubicin—uterine cancer	0.000152	0.000372	CcSEcCtD
Lenalidomide—Paraesthesia—Etoposide—uterine cancer	0.000152	0.000371	CcSEcCtD
Lenalidomide—Weight increased—Epirubicin—uterine cancer	0.000152	0.000371	CcSEcCtD
Lenalidomide—Pancreatitis—Doxorubicin—uterine cancer	0.000151	0.00037	CcSEcCtD
Lenalidomide—Weight decreased—Epirubicin—uterine cancer	0.000151	0.000369	CcSEcCtD
Lenalidomide—Dyspnoea—Etoposide—uterine cancer	0.000151	0.000369	CcSEcCtD
Lenalidomide—Hyperglycaemia—Epirubicin—uterine cancer	0.00015	0.000368	CcSEcCtD
Lenalidomide—Somnolence—Etoposide—uterine cancer	0.00015	0.000368	CcSEcCtD
Lenalidomide—Angina pectoris—Doxorubicin—uterine cancer	0.00015	0.000367	CcSEcCtD
Lenalidomide—Pneumonia—Epirubicin—uterine cancer	0.000149	0.000365	CcSEcCtD
Lenalidomide—Infestation—Epirubicin—uterine cancer	0.000148	0.000363	CcSEcCtD
Lenalidomide—Infestation NOS—Epirubicin—uterine cancer	0.000148	0.000363	CcSEcCtD
Lenalidomide—Vomiting—Dactinomycin—uterine cancer	0.000148	0.000363	CcSEcCtD
Lenalidomide—Bronchitis—Doxorubicin—uterine cancer	0.000148	0.000363	CcSEcCtD
Lenalidomide—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000147	0.00036	CcSEcCtD
Lenalidomide—Rash—Dactinomycin—uterine cancer	0.000147	0.00036	CcSEcCtD
Lenalidomide—Decreased appetite—Etoposide—uterine cancer	0.000147	0.000359	CcSEcCtD
Lenalidomide—Pancytopenia—Doxorubicin—uterine cancer	0.000146	0.000358	CcSEcCtD
Lenalidomide—Renal failure—Epirubicin—uterine cancer	0.000146	0.000357	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Etoposide—uterine cancer	0.000146	0.000357	CcSEcCtD
Lenalidomide—Fatigue—Etoposide—uterine cancer	0.000146	0.000356	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Epirubicin—uterine cancer	0.000146	0.000356	CcSEcCtD
Lenalidomide—Stomatitis—Epirubicin—uterine cancer	0.000145	0.000354	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	0.000145	0.00135	CbGpPWpGaD
Lenalidomide—Pain—Etoposide—uterine cancer	0.000144	0.000354	CcSEcCtD
Lenalidomide—Constipation—Etoposide—uterine cancer	0.000144	0.000354	CcSEcCtD
Lenalidomide—Urinary tract infection—Epirubicin—uterine cancer	0.000144	0.000353	CcSEcCtD
Lenalidomide—Conjunctivitis—Epirubicin—uterine cancer	0.000144	0.000353	CcSEcCtD
Lenalidomide—Dysuria—Doxorubicin—uterine cancer	0.000144	0.000353	CcSEcCtD
Lenalidomide—Neutropenia—Doxorubicin—uterine cancer	0.000144	0.000353	CcSEcCtD
Lenalidomide—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000143	0.00035	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—ESR1—uterine cancer	0.000143	0.00134	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—EP300—uterine cancer	0.000143	0.00133	CbGpPWpGaD
Lenalidomide—Sweating—Epirubicin—uterine cancer	0.000142	0.000348	CcSEcCtD
Lenalidomide—Pollakiuria—Doxorubicin—uterine cancer	0.000142	0.000348	CcSEcCtD
Lenalidomide—Haematuria—Epirubicin—uterine cancer	0.000142	0.000346	CcSEcCtD
Lenalidomide—Photosensitivity reaction—Doxorubicin—uterine cancer	0.000141	0.000344	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Epirubicin—uterine cancer	0.00014	0.000344	CcSEcCtD
Lenalidomide—Weight increased—Doxorubicin—uterine cancer	0.00014	0.000343	CcSEcCtD
Lenalidomide—Epistaxis—Epirubicin—uterine cancer	0.00014	0.000343	CcSEcCtD
Lenalidomide—Weight decreased—Doxorubicin—uterine cancer	0.000139	0.000341	CcSEcCtD
Lenalidomide—Sinusitis—Epirubicin—uterine cancer	0.000139	0.000341	CcSEcCtD
Lenalidomide—Feeling abnormal—Etoposide—uterine cancer	0.000139	0.000341	CcSEcCtD
Lenalidomide—Hyperglycaemia—Doxorubicin—uterine cancer	0.000139	0.00034	CcSEcCtD
Lenalidomide—Nausea—Dactinomycin—uterine cancer	0.000139	0.000339	CcSEcCtD
Lenalidomide—Agranulocytosis—Epirubicin—uterine cancer	0.000139	0.000339	CcSEcCtD
Lenalidomide—Pneumonia—Doxorubicin—uterine cancer	0.000138	0.000338	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Etoposide—uterine cancer	0.000138	0.000338	CcSEcCtD
Lenalidomide—Infestation NOS—Doxorubicin—uterine cancer	0.000137	0.000336	CcSEcCtD
Lenalidomide—Infestation—Doxorubicin—uterine cancer	0.000137	0.000336	CcSEcCtD
Lenalidomide—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.000136	0.000333	CcSEcCtD
Lenalidomide—Bradycardia—Epirubicin—uterine cancer	0.000136	0.000332	CcSEcCtD
Lenalidomide—Renal failure—Doxorubicin—uterine cancer	0.000135	0.00033	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Doxorubicin—uterine cancer	0.000135	0.00033	CcSEcCtD
Lenalidomide—Urticaria—Etoposide—uterine cancer	0.000134	0.000328	CcSEcCtD
Lenalidomide—Haemoglobin—Epirubicin—uterine cancer	0.000134	0.000328	CcSEcCtD
Lenalidomide—Stomatitis—Doxorubicin—uterine cancer	0.000134	0.000328	CcSEcCtD
Lenalidomide—Rhinitis—Epirubicin—uterine cancer	0.000134	0.000327	CcSEcCtD
Lenalidomide—Abdominal pain—Etoposide—uterine cancer	0.000134	0.000327	CcSEcCtD
Lenalidomide—Body temperature increased—Etoposide—uterine cancer	0.000134	0.000327	CcSEcCtD
Lenalidomide—Urinary tract infection—Doxorubicin—uterine cancer	0.000134	0.000327	CcSEcCtD
Lenalidomide—Conjunctivitis—Doxorubicin—uterine cancer	0.000134	0.000327	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—NRAS—uterine cancer	0.000133	0.00125	CbGpPWpGaD
Lenalidomide—Haemorrhage—Epirubicin—uterine cancer	0.000133	0.000326	CcSEcCtD
Lenalidomide—Hepatitis—Epirubicin—uterine cancer	0.000133	0.000326	CcSEcCtD
Lenalidomide—Hypoaesthesia—Epirubicin—uterine cancer	0.000133	0.000325	CcSEcCtD
Lenalidomide—Pharyngitis—Epirubicin—uterine cancer	0.000132	0.000324	CcSEcCtD
Lenalidomide—Sweating—Doxorubicin—uterine cancer	0.000132	0.000322	CcSEcCtD
Lenalidomide—Urinary tract disorder—Epirubicin—uterine cancer	0.000132	0.000322	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	0.000131	0.00123	CbGpPWpGaD
Lenalidomide—Oedema peripheral—Epirubicin—uterine cancer	0.000131	0.000321	CcSEcCtD
Lenalidomide—Haematuria—Doxorubicin—uterine cancer	0.000131	0.000321	CcSEcCtD
Lenalidomide—Connective tissue disorder—Epirubicin—uterine cancer	0.000131	0.000321	CcSEcCtD
Lenalidomide—Urethral disorder—Epirubicin—uterine cancer	0.000131	0.00032	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Doxorubicin—uterine cancer	0.00013	0.000318	CcSEcCtD
Lenalidomide—Epistaxis—Doxorubicin—uterine cancer	0.00013	0.000317	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	0.000129	0.00121	CbGpPWpGaD
Lenalidomide—Sinusitis—Doxorubicin—uterine cancer	0.000129	0.000315	CcSEcCtD
Lenalidomide—Visual impairment—Epirubicin—uterine cancer	0.000128	0.000314	CcSEcCtD
Lenalidomide—Agranulocytosis—Doxorubicin—uterine cancer	0.000128	0.000314	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—CXCL8—uterine cancer	0.000127	0.00119	CbGpPWpGaD
Lenalidomide—Erythema multiforme—Epirubicin—uterine cancer	0.000126	0.000308	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CCL2—uterine cancer	0.000126	0.00118	CbGpPWpGaD
Lenalidomide—Bradycardia—Doxorubicin—uterine cancer	0.000126	0.000307	CcSEcCtD
Lenalidomide—Eye disorder—Epirubicin—uterine cancer	0.000125	0.000305	CcSEcCtD
Lenalidomide—Hypersensitivity—Etoposide—uterine cancer	0.000124	0.000305	CcSEcCtD
Lenalidomide—Tinnitus—Epirubicin—uterine cancer	0.000124	0.000304	CcSEcCtD
Lenalidomide—Haemoglobin—Doxorubicin—uterine cancer	0.000124	0.000303	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	0.000124	0.00116	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CXCL8—uterine cancer	0.000124	0.00116	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CDKN1B—uterine cancer	0.000124	0.00116	CbGpPWpGaD
Lenalidomide—Flushing—Epirubicin—uterine cancer	0.000124	0.000303	CcSEcCtD
Lenalidomide—Cardiac disorder—Epirubicin—uterine cancer	0.000124	0.000303	CcSEcCtD
Lenalidomide—Rhinitis—Doxorubicin—uterine cancer	0.000124	0.000303	CcSEcCtD
Lenalidomide—Hepatitis—Doxorubicin—uterine cancer	0.000123	0.000302	CcSEcCtD
Lenalidomide—Haemorrhage—Doxorubicin—uterine cancer	0.000123	0.000302	CcSEcCtD
Lenalidomide—Hypoaesthesia—Doxorubicin—uterine cancer	0.000123	0.0003	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—EP300—uterine cancer	0.000123	0.00115	CbGpPWpGaD
Lenalidomide—Pharyngitis—Doxorubicin—uterine cancer	0.000122	0.0003	CcSEcCtD
Lenalidomide—Urinary tract disorder—Doxorubicin—uterine cancer	0.000122	0.000298	CcSEcCtD
Lenalidomide—Oedema peripheral—Doxorubicin—uterine cancer	0.000121	0.000297	CcSEcCtD
Lenalidomide—Asthenia—Etoposide—uterine cancer	0.000121	0.000297	CcSEcCtD
Lenalidomide—Connective tissue disorder—Doxorubicin—uterine cancer	0.000121	0.000297	CcSEcCtD
Lenalidomide—Angiopathy—Epirubicin—uterine cancer	0.000121	0.000296	CcSEcCtD
Lenalidomide—Urethral disorder—Doxorubicin—uterine cancer	0.000121	0.000296	CcSEcCtD
Lenalidomide—Immune system disorder—Epirubicin—uterine cancer	0.00012	0.000295	CcSEcCtD
Lenalidomide—Mediastinal disorder—Epirubicin—uterine cancer	0.00012	0.000294	CcSEcCtD
Lenalidomide—Chills—Epirubicin—uterine cancer	0.00012	0.000293	CcSEcCtD
Lenalidomide—Pruritus—Etoposide—uterine cancer	0.00012	0.000292	CcSEcCtD
Lenalidomide—Arrhythmia—Epirubicin—uterine cancer	0.000119	0.000291	CcSEcCtD
Lenalidomide—Visual impairment—Doxorubicin—uterine cancer	0.000119	0.000291	CcSEcCtD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.000119	0.00111	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	0.000118	0.0011	CbGpPWpGaD
Lenalidomide—Alopecia—Epirubicin—uterine cancer	0.000118	0.000288	CcSEcCtD
Lenalidomide—Mental disorder—Epirubicin—uterine cancer	0.000117	0.000286	CcSEcCtD
Lenalidomide—Erythema multiforme—Doxorubicin—uterine cancer	0.000117	0.000285	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—uterine cancer	0.000116	0.00109	CbGpPWpGaD
Lenalidomide—Malnutrition—Epirubicin—uterine cancer	0.000116	0.000284	CcSEcCtD
Lenalidomide—Erythema—Epirubicin—uterine cancer	0.000116	0.000284	CcSEcCtD
Lenalidomide—Diarrhoea—Etoposide—uterine cancer	0.000116	0.000283	CcSEcCtD
Lenalidomide—Eye disorder—Doxorubicin—uterine cancer	0.000115	0.000282	CcSEcCtD
Lenalidomide—Tinnitus—Doxorubicin—uterine cancer	0.000115	0.000281	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—KRAS—uterine cancer	0.000115	0.00107	CbGpPWpGaD
Lenalidomide—Cardiac disorder—Doxorubicin—uterine cancer	0.000114	0.00028	CcSEcCtD
Lenalidomide—Flushing—Doxorubicin—uterine cancer	0.000114	0.00028	CcSEcCtD
Lenalidomide—Flatulence—Epirubicin—uterine cancer	0.000114	0.00028	CcSEcCtD
Lenalidomide—Tension—Epirubicin—uterine cancer	0.000114	0.000279	CcSEcCtD
Lenalidomide—Dysgeusia—Epirubicin—uterine cancer	0.000114	0.000278	CcSEcCtD
Lenalidomide—Nervousness—Epirubicin—uterine cancer	0.000113	0.000276	CcSEcCtD
Lenalidomide—Back pain—Epirubicin—uterine cancer	0.000112	0.000275	CcSEcCtD
Lenalidomide—Angiopathy—Doxorubicin—uterine cancer	0.000112	0.000274	CcSEcCtD
Lenalidomide—Dizziness—Etoposide—uterine cancer	0.000112	0.000273	CcSEcCtD
Lenalidomide—Muscle spasms—Epirubicin—uterine cancer	0.000112	0.000273	CcSEcCtD
Lenalidomide—Immune system disorder—Doxorubicin—uterine cancer	0.000111	0.000273	CcSEcCtD
Lenalidomide—Mediastinal disorder—Doxorubicin—uterine cancer	0.000111	0.000272	CcSEcCtD
Lenalidomide—Chills—Doxorubicin—uterine cancer	0.000111	0.000271	CcSEcCtD
Lenalidomide—Arrhythmia—Doxorubicin—uterine cancer	0.00011	0.00027	CcSEcCtD
Lenalidomide—Vision blurred—Epirubicin—uterine cancer	0.000109	0.000268	CcSEcCtD
Lenalidomide—Alopecia—Doxorubicin—uterine cancer	0.000109	0.000267	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—SRD5A2—uterine cancer	0.000108	0.00101	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NDUFB11—uterine cancer	0.000108	0.00101	CbGpPWpGaD
Lenalidomide—Mental disorder—Doxorubicin—uterine cancer	0.000108	0.000264	CcSEcCtD
Lenalidomide—Ill-defined disorder—Epirubicin—uterine cancer	0.000108	0.000263	CcSEcCtD
Lenalidomide—Vomiting—Etoposide—uterine cancer	0.000107	0.000263	CcSEcCtD
Lenalidomide—Erythema—Doxorubicin—uterine cancer	0.000107	0.000263	CcSEcCtD
Lenalidomide—Malnutrition—Doxorubicin—uterine cancer	0.000107	0.000263	CcSEcCtD
Lenalidomide—Anaemia—Epirubicin—uterine cancer	0.000107	0.000262	CcSEcCtD
Lenalidomide—Agitation—Epirubicin—uterine cancer	0.000107	0.000261	CcSEcCtD
Lenalidomide—Rash—Etoposide—uterine cancer	0.000107	0.000261	CcSEcCtD
Lenalidomide—Dermatitis—Etoposide—uterine cancer	0.000106	0.00026	CcSEcCtD
Lenalidomide—Headache—Etoposide—uterine cancer	0.000106	0.000259	CcSEcCtD
Lenalidomide—Flatulence—Doxorubicin—uterine cancer	0.000106	0.000259	CcSEcCtD
Lenalidomide—Tension—Doxorubicin—uterine cancer	0.000105	0.000258	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	0.000105	0.000984	CbGpPWpGaD
Lenalidomide—Dysgeusia—Doxorubicin—uterine cancer	0.000105	0.000257	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—ERBB2—uterine cancer	0.000105	0.00098	CbGpPWpGaD
Lenalidomide—Malaise—Epirubicin—uterine cancer	0.000105	0.000256	CcSEcCtD
Lenalidomide—Nervousness—Doxorubicin—uterine cancer	0.000104	0.000255	CcSEcCtD
Lenalidomide—Vertigo—Epirubicin—uterine cancer	0.000104	0.000255	CcSEcCtD
Lenalidomide—Syncope—Epirubicin—uterine cancer	0.000104	0.000255	CcSEcCtD
Lenalidomide—Leukopenia—Epirubicin—uterine cancer	0.000104	0.000254	CcSEcCtD
Lenalidomide—Back pain—Doxorubicin—uterine cancer	0.000104	0.000254	CcSEcCtD
Lenalidomide—Muscle spasms—Doxorubicin—uterine cancer	0.000103	0.000253	CcSEcCtD
Lenalidomide—Palpitations—Epirubicin—uterine cancer	0.000103	0.000251	CcSEcCtD
Lenalidomide—Loss of consciousness—Epirubicin—uterine cancer	0.000102	0.00025	CcSEcCtD
Lenalidomide—Cough—Epirubicin—uterine cancer	0.000101	0.000248	CcSEcCtD
Lenalidomide—Vision blurred—Doxorubicin—uterine cancer	0.000101	0.000248	CcSEcCtD
Lenalidomide—PTGS2—Disease—AKR1B10—uterine cancer	0.000101	0.000941	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—VEGFA—uterine cancer	0.000101	0.000941	CbGpPWpGaD
Lenalidomide—Nausea—Etoposide—uterine cancer	0.0001	0.000246	CcSEcCtD
Lenalidomide—Hypertension—Epirubicin—uterine cancer	0.0001	0.000245	CcSEcCtD
Lenalidomide—Ill-defined disorder—Doxorubicin—uterine cancer	9.96e-05	0.000244	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	9.94e-05	0.000929	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CXCL8—uterine cancer	9.93e-05	0.000929	CbGpPWpGaD
Lenalidomide—Anaemia—Doxorubicin—uterine cancer	9.92e-05	0.000243	CcSEcCtD
Lenalidomide—Chest pain—Epirubicin—uterine cancer	9.88e-05	0.000242	CcSEcCtD
Lenalidomide—Myalgia—Epirubicin—uterine cancer	9.88e-05	0.000242	CcSEcCtD
Lenalidomide—Arthralgia—Epirubicin—uterine cancer	9.88e-05	0.000242	CcSEcCtD
Lenalidomide—Agitation—Doxorubicin—uterine cancer	9.87e-05	0.000241	CcSEcCtD
Lenalidomide—Anxiety—Epirubicin—uterine cancer	9.84e-05	0.000241	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	9.81e-05	0.00024	CcSEcCtD
Lenalidomide—Discomfort—Epirubicin—uterine cancer	9.76e-05	0.000239	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—HRAS—uterine cancer	9.76e-05	0.000913	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CDKN1B—uterine cancer	9.7e-05	0.000907	CbGpPWpGaD
Lenalidomide—Malaise—Doxorubicin—uterine cancer	9.68e-05	0.000237	CcSEcCtD
Lenalidomide—Dry mouth—Epirubicin—uterine cancer	9.66e-05	0.000236	CcSEcCtD
Lenalidomide—Vertigo—Doxorubicin—uterine cancer	9.65e-05	0.000236	CcSEcCtD
Lenalidomide—Syncope—Doxorubicin—uterine cancer	9.63e-05	0.000236	CcSEcCtD
Lenalidomide—Leukopenia—Doxorubicin—uterine cancer	9.61e-05	0.000235	CcSEcCtD
Lenalidomide—Confusional state—Epirubicin—uterine cancer	9.55e-05	0.000234	CcSEcCtD
Lenalidomide—Palpitations—Doxorubicin—uterine cancer	9.49e-05	0.000232	CcSEcCtD
Lenalidomide—Oedema—Epirubicin—uterine cancer	9.47e-05	0.000232	CcSEcCtD
Lenalidomide—Loss of consciousness—Doxorubicin—uterine cancer	9.44e-05	0.000231	CcSEcCtD
Lenalidomide—Infection—Epirubicin—uterine cancer	9.41e-05	0.00023	CcSEcCtD
Lenalidomide—Cough—Doxorubicin—uterine cancer	9.37e-05	0.000229	CcSEcCtD
Lenalidomide—Shock—Epirubicin—uterine cancer	9.32e-05	0.000228	CcSEcCtD
Lenalidomide—Nervous system disorder—Epirubicin—uterine cancer	9.29e-05	0.000227	CcSEcCtD
Lenalidomide—Thrombocytopenia—Epirubicin—uterine cancer	9.27e-05	0.000227	CcSEcCtD
Lenalidomide—Hypertension—Doxorubicin—uterine cancer	9.27e-05	0.000227	CcSEcCtD
Lenalidomide—Tachycardia—Epirubicin—uterine cancer	9.24e-05	0.000226	CcSEcCtD
Lenalidomide—Skin disorder—Epirubicin—uterine cancer	9.2e-05	0.000225	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CTNNB1—uterine cancer	9.17e-05	0.000857	CbGpPWpGaD
Lenalidomide—Hyperhidrosis—Epirubicin—uterine cancer	9.15e-05	0.000224	CcSEcCtD
Lenalidomide—Myalgia—Doxorubicin—uterine cancer	9.14e-05	0.000224	CcSEcCtD
Lenalidomide—Chest pain—Doxorubicin—uterine cancer	9.14e-05	0.000224	CcSEcCtD
Lenalidomide—Arthralgia—Doxorubicin—uterine cancer	9.14e-05	0.000224	CcSEcCtD
Lenalidomide—Anxiety—Doxorubicin—uterine cancer	9.11e-05	0.000223	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	9.09e-05	0.00085	CbGpPWpGaD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	9.08e-05	0.000222	CcSEcCtD
Lenalidomide—Discomfort—Doxorubicin—uterine cancer	9.03e-05	0.000221	CcSEcCtD
Lenalidomide—Anorexia—Epirubicin—uterine cancer	9.03e-05	0.000221	CcSEcCtD
Lenalidomide—Dry mouth—Doxorubicin—uterine cancer	8.94e-05	0.000219	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—PTEN—uterine cancer	8.93e-05	0.000836	CbGpPWpGaD
Lenalidomide—Hypotension—Epirubicin—uterine cancer	8.85e-05	0.000217	CcSEcCtD
Lenalidomide—Confusional state—Doxorubicin—uterine cancer	8.83e-05	0.000216	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	8.78e-05	0.000821	CbGpPWpGaD
Lenalidomide—Oedema—Doxorubicin—uterine cancer	8.76e-05	0.000214	CcSEcCtD
Lenalidomide—Infection—Doxorubicin—uterine cancer	8.7e-05	0.000213	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Epirubicin—uterine cancer	8.63e-05	0.000211	CcSEcCtD
Lenalidomide—Shock—Doxorubicin—uterine cancer	8.62e-05	0.000211	CcSEcCtD
Lenalidomide—Nervous system disorder—Doxorubicin—uterine cancer	8.59e-05	0.00021	CcSEcCtD
Lenalidomide—Thrombocytopenia—Doxorubicin—uterine cancer	8.58e-05	0.00021	CcSEcCtD
Lenalidomide—Insomnia—Epirubicin—uterine cancer	8.57e-05	0.00021	CcSEcCtD
Lenalidomide—Tachycardia—Doxorubicin—uterine cancer	8.55e-05	0.000209	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—EP300—uterine cancer	8.52e-05	0.000797	CbGpPWpGaD
Lenalidomide—Skin disorder—Doxorubicin—uterine cancer	8.51e-05	0.000208	CcSEcCtD
Lenalidomide—Paraesthesia—Epirubicin—uterine cancer	8.5e-05	0.000208	CcSEcCtD
Lenalidomide—Hyperhidrosis—Doxorubicin—uterine cancer	8.47e-05	0.000207	CcSEcCtD
Lenalidomide—Dyspnoea—Epirubicin—uterine cancer	8.44e-05	0.000207	CcSEcCtD
Lenalidomide—Somnolence—Epirubicin—uterine cancer	8.42e-05	0.000206	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	8.42e-05	0.000787	CbGpPWpGaD
Lenalidomide—Anorexia—Doxorubicin—uterine cancer	8.35e-05	0.000204	CcSEcCtD
Lenalidomide—Dyspepsia—Epirubicin—uterine cancer	8.34e-05	0.000204	CcSEcCtD
Lenalidomide—PTGS2—Disease—RNF43—uterine cancer	8.33e-05	0.00078	CbGpPWpGaD
Lenalidomide—Decreased appetite—Epirubicin—uterine cancer	8.23e-05	0.000201	CcSEcCtD
Lenalidomide—Hypotension—Doxorubicin—uterine cancer	8.19e-05	0.0002	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Epirubicin—uterine cancer	8.18e-05	0.0002	CcSEcCtD
Lenalidomide—Fatigue—Epirubicin—uterine cancer	8.16e-05	0.0002	CcSEcCtD
Lenalidomide—Pain—Epirubicin—uterine cancer	8.1e-05	0.000198	CcSEcCtD
Lenalidomide—Constipation—Epirubicin—uterine cancer	8.1e-05	0.000198	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—VEGFA—uterine cancer	8.07e-05	0.000755	CbGpPWpGaD
Lenalidomide—Musculoskeletal discomfort—Doxorubicin—uterine cancer	7.98e-05	0.000195	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—NRAS—uterine cancer	7.97e-05	0.000745	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	7.95e-05	0.000744	CbGpPWpGaD
Lenalidomide—Insomnia—Doxorubicin—uterine cancer	7.93e-05	0.000194	CcSEcCtD
Lenalidomide—Paraesthesia—Doxorubicin—uterine cancer	7.87e-05	0.000193	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—AKR1B1—uterine cancer	7.83e-05	0.000733	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—STAR—uterine cancer	7.83e-05	0.000733	CbGpPWpGaD
Lenalidomide—Dyspnoea—Doxorubicin—uterine cancer	7.81e-05	0.000191	CcSEcCtD
Lenalidomide—Feeling abnormal—Epirubicin—uterine cancer	7.8e-05	0.000191	CcSEcCtD
Lenalidomide—Somnolence—Doxorubicin—uterine cancer	7.79e-05	0.000191	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—TP53—uterine cancer	7.77e-05	0.000727	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	7.75e-05	0.000725	CbGpPWpGaD
Lenalidomide—Gastrointestinal pain—Epirubicin—uterine cancer	7.74e-05	0.000189	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	7.74e-05	0.000724	CbGpPWpGaD
Lenalidomide—Dyspepsia—Doxorubicin—uterine cancer	7.71e-05	0.000189	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—NDUFB11—uterine cancer	7.68e-05	0.000718	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SRD5A2—uterine cancer	7.68e-05	0.000718	CbGpPWpGaD
Lenalidomide—Decreased appetite—Doxorubicin—uterine cancer	7.62e-05	0.000186	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Doxorubicin—uterine cancer	7.56e-05	0.000185	CcSEcCtD
Lenalidomide—Fatigue—Doxorubicin—uterine cancer	7.55e-05	0.000185	CcSEcCtD
Lenalidomide—Urticaria—Epirubicin—uterine cancer	7.52e-05	0.000184	CcSEcCtD
Lenalidomide—Constipation—Doxorubicin—uterine cancer	7.49e-05	0.000183	CcSEcCtD
Lenalidomide—Pain—Doxorubicin—uterine cancer	7.49e-05	0.000183	CcSEcCtD
Lenalidomide—Body temperature increased—Epirubicin—uterine cancer	7.49e-05	0.000183	CcSEcCtD
Lenalidomide—Abdominal pain—Epirubicin—uterine cancer	7.49e-05	0.000183	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—AKT1—uterine cancer	7.41e-05	0.000693	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	7.39e-05	0.000691	CbGpPWpGaD
Lenalidomide—Feeling abnormal—Doxorubicin—uterine cancer	7.22e-05	0.000177	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Doxorubicin—uterine cancer	7.17e-05	0.000175	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	7e-05	0.000655	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Epirubicin—uterine cancer	6.98e-05	0.000171	CcSEcCtD
Lenalidomide—Urticaria—Doxorubicin—uterine cancer	6.96e-05	0.00017	CcSEcCtD
Lenalidomide—Abdominal pain—Doxorubicin—uterine cancer	6.93e-05	0.00017	CcSEcCtD
Lenalidomide—Body temperature increased—Doxorubicin—uterine cancer	6.93e-05	0.00017	CcSEcCtD
Lenalidomide—PTGS2—Disease—AKR1C1—uterine cancer	6.86e-05	0.000642	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—KRAS—uterine cancer	6.86e-05	0.000642	CbGpPWpGaD
Lenalidomide—Asthenia—Epirubicin—uterine cancer	6.79e-05	0.000166	CcSEcCtD
Lenalidomide—Pruritus—Epirubicin—uterine cancer	6.7e-05	0.000164	CcSEcCtD
Lenalidomide—Diarrhoea—Epirubicin—uterine cancer	6.48e-05	0.000159	CcSEcCtD
Lenalidomide—Hypersensitivity—Doxorubicin—uterine cancer	6.46e-05	0.000158	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	6.44e-05	0.000603	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PIK3CA—uterine cancer	6.3e-05	0.000589	CbGpPWpGaD
Lenalidomide—Asthenia—Doxorubicin—uterine cancer	6.29e-05	0.000154	CcSEcCtD
Lenalidomide—Dizziness—Epirubicin—uterine cancer	6.26e-05	0.000153	CcSEcCtD
Lenalidomide—Pruritus—Doxorubicin—uterine cancer	6.2e-05	0.000152	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—POLD1—uterine cancer	6.15e-05	0.000575	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TP53—uterine cancer	6.1e-05	0.00057	CbGpPWpGaD
Lenalidomide—Vomiting—Epirubicin—uterine cancer	6.02e-05	0.000147	CcSEcCtD
Lenalidomide—Diarrhoea—Doxorubicin—uterine cancer	6e-05	0.000147	CcSEcCtD
Lenalidomide—Rash—Epirubicin—uterine cancer	5.97e-05	0.000146	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	5.97e-05	0.000558	CbGpPWpGaD
Lenalidomide—Dermatitis—Epirubicin—uterine cancer	5.97e-05	0.000146	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	5.95e-05	0.000557	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—DCN—uterine cancer	5.94e-05	0.000556	CbGpPWpGaD
Lenalidomide—Headache—Epirubicin—uterine cancer	5.93e-05	0.000145	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—HRAS—uterine cancer	5.83e-05	0.000545	CbGpPWpGaD
Lenalidomide—Dizziness—Doxorubicin—uterine cancer	5.79e-05	0.000142	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—AKR1C1—uterine cancer	5.75e-05	0.000538	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	5.64e-05	0.000527	CbGpPWpGaD
Lenalidomide—Nausea—Epirubicin—uterine cancer	5.62e-05	0.000138	CcSEcCtD
Lenalidomide—Vomiting—Doxorubicin—uterine cancer	5.57e-05	0.000136	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—AKR1B1—uterine cancer	5.55e-05	0.000519	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—STAR—uterine cancer	5.55e-05	0.000519	CbGpPWpGaD
Lenalidomide—Rash—Doxorubicin—uterine cancer	5.52e-05	0.000135	CcSEcCtD
Lenalidomide—Dermatitis—Doxorubicin—uterine cancer	5.52e-05	0.000135	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	5.49e-05	0.000514	CbGpPWpGaD
Lenalidomide—Headache—Doxorubicin—uterine cancer	5.49e-05	0.000134	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	5.47e-05	0.000511	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	5.29e-05	0.000495	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—AKR1C3—uterine cancer	5.28e-05	0.000494	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	5.24e-05	0.00049	CbGpPWpGaD
Lenalidomide—Nausea—Doxorubicin—uterine cancer	5.2e-05	0.000127	CcSEcCtD
Lenalidomide—PTGS2—Disease—HMGA1—uterine cancer	5.15e-05	0.000482	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—AKT1—uterine cancer	5.15e-05	0.000482	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—RRM2—uterine cancer	5.12e-05	0.000479	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—DCN—uterine cancer	4.97e-05	0.000465	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	4.96e-05	0.000464	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FBXW7—uterine cancer	4.71e-05	0.000441	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP11A1—uterine cancer	4.69e-05	0.000438	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	4.47e-05	0.000418	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—AKR1C3—uterine cancer	4.43e-05	0.000414	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—POLD1—uterine cancer	4.36e-05	0.000407	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	4.22e-05	0.000395	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—AKR1C1—uterine cancer	4.07e-05	0.000381	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	3.88e-05	0.000363	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	3.75e-05	0.000351	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CDKN2B—uterine cancer	3.69e-05	0.000345	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—RRM2—uterine cancer	3.63e-05	0.00034	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—DCN—uterine cancer	3.53e-05	0.00033	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—STK11—uterine cancer	3.45e-05	0.000322	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP19A1—uterine cancer	3.45e-05	0.000322	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SMAD3—uterine cancer	3.37e-05	0.000315	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP11A1—uterine cancer	3.32e-05	0.000311	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	3.24e-05	0.000303	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FGFR2—uterine cancer	3.21e-05	0.000301	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	3.17e-05	0.000296	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—AKR1C3—uterine cancer	3.14e-05	0.000293	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MTHFR—uterine cancer	3.09e-05	0.000289	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	3.09e-05	0.000289	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—MTHFR—uterine cancer	2.59e-05	0.000242	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—STK11—uterine cancer	2.44e-05	0.000229	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP19A1—uterine cancer	2.44e-05	0.000229	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.28e-05	0.000214	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ERBB2—uterine cancer	2.02e-05	0.000189	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CDKN1B—uterine cancer	1.87e-05	0.000175	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—MTHFR—uterine cancer	1.84e-05	0.000172	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CTNNB1—uterine cancer	1.77e-05	0.000165	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PTEN—uterine cancer	1.72e-05	0.000161	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—EP300—uterine cancer	1.64e-05	0.000154	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NRAS—uterine cancer	1.54e-05	0.000144	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PTEN—uterine cancer	1.44e-05	0.000135	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—EP300—uterine cancer	1.37e-05	0.000129	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—KRAS—uterine cancer	1.32e-05	0.000124	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PIK3CA—uterine cancer	1.21e-05	0.000114	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HRAS—uterine cancer	1.12e-05	0.000105	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTEN—uterine cancer	1.02e-05	9.56e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CA—uterine cancer	1.02e-05	9.51e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—AKT1—uterine cancer	9.92e-06	9.28e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—EP300—uterine cancer	9.74e-06	9.11e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—AKT1—uterine cancer	8.31e-06	7.77e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CA—uterine cancer	7.21e-06	6.74e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—AKT1—uterine cancer	5.89e-06	5.51e-05	CbGpPWpGaD
